Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review

Xiao, Ya-Qi; Long, Jiao; Zhang, Shuang-Shuang; Zhu, Yuan-Yuan; Gu, Shuang-Xi

doi:10.1016/j.bioorg.2024.107380

Cited by 5 publications

(2 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These inhibitors have demonstrated favorable oral bioavailability and prolonged half-lives, suggesting enhanced in vivo efficacy and decreased potential for drug interactions. 95,96 3.2.1. Covalent Inhibitors.…”

Section: Haloacetyl-containing Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M^pro)

Yang,

Luo,

Zhang

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Since 2019, the novel coronavirus (SARS-CoV-2) has caused significant morbidity and millions of deaths worldwide. The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2 and its variants, has further highlighted the urgent need for the development of effective therapeutic agents. Currently, the highly conserved and broadspectrum nature of main proteases (M pro ) renders them of great importance in the field of inhibitor study. In this study, we categorize inhibitors targeting M pro into three major groups: mimetic, nonmimetic, and natural inhibitors. We then present the research progress of these inhibitors in detail, including their mechanism of action, antiviral activity, pharmacokinetic properties, animal experiments, and clinical studies. This review aims to provide valuable insights and potential avenues for the development of more effective antiviral drugs against SARS-CoV-2.

show abstract

Section: Haloacetyl-containing Inhibitorsmentioning

confidence: 99%

“…Nonpeptidomimetic inhibitors, primarily originating from high-throughput screening, are categorized as either covalent or noncovalent inhibitors. These inhibitors have demonstrated favorable oral bioavailability and prolonged half-lives, suggesting enhanced in vivo efficacy and decreased potential for drug interactions. , …”

Section: Inhibitors Targeting Mpromentioning

confidence: 99%